Self-examination low-cost full-field OCT (SELFF-OCT) allows treatment decision for age related macular degeneration (AMD) and diabetic macular edema (DME) with high sensitivity and specificity: clinical pilot study

Helge M. Sudkamp; Claus von der Burchard; Moritz Moltmann; Peter Koch; Malte vom Endt; Michael Münst; Christoph Ehlken; Timo Kepp; Dirk Theisen-Kunde; Reginald Birngruber; Johann Roider; Gereon Hüttmann

doi:10.1117/12.2583041

5 March 2021 Self-examination low-cost full-field OCT (SELFF-OCT) allows treatment decision for age related macular degeneration (AMD) and diabetic macular edema (DME) with high sensitivity and specificity: clinical pilot study

Helge M. Sudkamp, Claus von der Burchard, Moritz Moltmann, Peter Koch, Malte vom Endt, Michael Münst, Christoph Ehlken, Timo Kepp, Dirk Theisen-Kunde, Reginald Birngruber, Johann Roider, Gereon Hüttmann

Author Affiliations +

Proceedings Volume 11623, Ophthalmic Technologies XXXI; 116230Z (2021) https://doi.org/10.1117/12.2583041
Event: SPIE BiOS, 2021, Online Only

Abstract

The treatment of macular diseases requires frequent monitoring by optical coherence tomography (OCT). Home monitoring would reduce the burden of frequent clinical visits and increase therapy adherence. In a pilot study with 47 patients having different macular diseases we tested a proprietary self-examination low-cost full-field OCT (SELFF-OCT). For comparison, scans with a standard clinical spectral domain OCT were taken. Data was graded by a reading center. Patients were able to successfully acquire images that were clinically gradable for 85% of the included eyes. The sensitivity and specificity for an anti-VEGF treatment decision based on the SELFF-OCT was 0.94 and 0.95, respectively.

Conference Presentation

Citation Download Citation

Helge M. Sudkamp, Claus von der Burchard, Moritz Moltmann, Peter Koch, Malte vom Endt, Michael Münst, Christoph Ehlken, Timo Kepp, Dirk Theisen-Kunde, Reginald Birngruber, Johann Roider, and Gereon Hüttmann "Self-examination low-cost full-field OCT (SELFF-OCT) allows treatment decision for age related macular degeneration (AMD) and diabetic macular edema (DME) with high sensitivity and specificity: clinical pilot study", Proc. SPIE 11623, Ophthalmic Technologies XXXI, 116230Z (5 March 2021); https://doi.org/10.1117/12.2583041

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available